Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BIIB021

Generic Name: BIIB021

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₅ClN_₆O

CAS Number: 848695-25-0

Unique Ingredient Identifier: 851B9FQ7Q0

Overview

BIIB021 has been investigated for the treatment of Tumors and Lymphoma.

Background

BIIB021 has been investigated for the treatment of Tumors and Lymphoma.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors

Phase 1

Completed

Posted: 2009/11/20

Sponsor:Biogen

ID:NCT01017198

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Phase 2

Completed

Posted: 2009/10/29

Sponsor:Biogen

ID:NCT01004081

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Phase 1

Completed

Posted: 2008/02/20

Sponsor:Biogen

ID:NCT00618735

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

Phase 2

Completed

Posted: 2008/02/20

Sponsor:Biogen

ID:NCT00618319

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

Phase 1

Completed

Posted: 2006/12/18

Sponsor:Biogen

ID:NCT00412412

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy